Hunt S, Elg F
Lead Nurse Advanced Nurse Practitioner, Wellway Medical Group, Northumberland, Berwick Upon Tweed, UK.
Consultant Statistician, Pracipio Ltd, London, UK.
J Wound Care. 2017 Sep 2;26(9):558-568. doi: 10.12968/jowc.2017.26.9.558.
To investigate wound healing after application of adjunctive topical haemoglobin spray in patients with chronic wounds.
Consecutive patients with a diversity of chronic wounds (defined as <40% reduction in wound size within 4 weeks) were treated with standard wound care plus haemoglobin spray and evaluated over a 26-week period. Results were compared with a retrospective cohort of 50 consecutive patients treated with standard wound care alone.
We evaluated 50 patients for a 26-week evaluation period, during which 45/50 patients (90%) treated with haemoglobin spray were completely healed compared with 19/50 retrospective control patients (38%) (p<0.001). Mean time to complete wound healing was 6.6 weeks (range: 3-22) in the haemoglobin spray group compared with 11.4 weeks (range: 3-25) in the control group (p=0.01). Cox proportional hazards analysis model adjusting for baseline wound size and months wound present also yielded significant treatment effects. Exudate, slough and pain levels were all reduced to a greater extent versus control group.
Haemoglobin spray resulted in a higher number of healed wounds and a faster rate of healing, as well as a positive impact on other wound parameters. These results are in accordance with other published data and supports the adjunctive use of haemoglobin spray in patients with a wide variety of chronic wounds of all sizes and origins.
研究在慢性伤口患者中应用辅助性局部血红蛋白喷雾后的伤口愈合情况。
连续纳入患有多种慢性伤口(定义为4周内伤口大小缩小<40%)的患者,给予标准伤口护理加血红蛋白喷雾治疗,并在26周内进行评估。将结果与一组回顾性队列中50例仅接受标准伤口护理的连续患者进行比较。
我们对50例患者进行了为期26周的评估,在此期间,接受血红蛋白喷雾治疗的45/50例患者(90%)完全愈合,而回顾性对照组的19/50例患者(38%)完全愈合(p<0.001)。血红蛋白喷雾组伤口完全愈合的平均时间为6.6周(范围:3 - 22周),而对照组为11.4周(范围:3 - 25周)(p = 0.01)。对基线伤口大小和伤口存在时间进行校正的Cox比例风险分析模型也产生了显著的治疗效果。与对照组相比,渗出物、腐肉和疼痛水平均有更大程度的降低。
血红蛋白喷雾使愈合的伤口数量增加、愈合速度加快,并对其他伤口参数产生积极影响。这些结果与其他已发表的数据一致,并支持在各种大小和来源的慢性伤口患者中辅助使用血红蛋白喷雾。